Alzheimer's pipeline
Track the mix of amyloid, tau, metabolic, and precision-style Alzheimer's programs worth watching.
Top programs in this hub
Starts with the highest-priority programs in the current dataset, then widens into the full bench below.
Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further rollout, label evolution, and follow-up data.
- Last verified
- 20 Apr 2026
Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Additional post-approval data and uptake signals.
- Last verified
- 20 Apr 2026
A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.
- Mechanism
- anti-amyloid oligomer modulation
- Modality
- small molecule
- Next catalyst
- Long-term extension updates and any signal on APOE4-enriched positioning.
- Last verified
- 20 Apr 2026
What defines this bench
Quick pattern read on the mechanisms and modalities currently showing up most often.
A disease-specific view of the main programs, the common mechanisms, and the related program pages.
All tracked Alzheimer's disease programs
Every program in the current watchlist for this disease, in priority order.
Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further rollout, label evolution, and follow-up data.
- Last verified
- 20 Apr 2026
Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Additional post-approval data and uptake signals.
- Last verified
- 20 Apr 2026
A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.
- Mechanism
- anti-amyloid oligomer modulation
- Modality
- small molecule
- Next catalyst
- Long-term extension updates and any signal on APOE4-enriched positioning.
- Last verified
- 20 Apr 2026
Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Recruitment updates and larger efficacy or safety read-throughs.
- Last verified
- 20 Apr 2026
A high-visibility metabolic intervention program that tests whether GLP-1 biology can matter in Alzheimer's disease.
- Mechanism
- GLP-1 receptor agonism
- Modality
- small molecule / peptide metabolic therapy
- Next catalyst
- Interpretation of Phase 3 read-throughs and what they imply for metabolic approaches to AD.
- Last verified
- 20 Apr 2026
Tau-lowering antisense program that matters because the field needs credible non-amyloid shots on goal.
- Mechanism
- tau antisense oligonucleotide
- Modality
- ASO
- Next catalyst
- Updated biomarker and dose-expansion signals.
- Last verified
- 20 Apr 2026
A serious tau program that matters because the Alzheimer's field still needs credible combination therapy attempts.
- Mechanism
- anti-MTBR tau antibody
- Modality
- monoclonal antibody
- Next catalyst
- Whether the tau-plus-amyloid combination thesis produces a clearer signal than monotherapy tracks.
- Last verified
- 20 Apr 2026
Roche's differentiated amyloid program designed for stronger CNS delivery dynamics.
- Mechanism
- anti-amyloid antibody with brain shuttle design
- Modality
- engineered antibody
- Next catalyst
- Mid-stage data maturity and competitive positioning updates.
- Last verified
- 20 Apr 2026
A vaccine-style Alzheimer's program that diversifies the monitor away from a monoclonal-antibody monoculture.
- Mechanism
- anti-amyloid active immunotherapy
- Modality
- therapeutic vaccine
- Next catalyst
- Further safety and immunogenicity read-throughs in prodromal and established Alzheimer's cohorts.
- Last verified
- 20 Apr 2026
Tau-directed antibody program that matters because Alzheimer's cannot stay a one-mechanism pipeline forever.
- Mechanism
- anti-tau antibody
- Modality
- monoclonal antibody
- Next catalyst
- Whether tau-antibody follow-through survives the broader amyloid-dominated landscape.
- Last verified
- 20 Apr 2026
Related pages
Research, key targets, Discover, and ways to contribute.
Other disease hubs
Other disease areas in the pipeline.
Follow Parkinson's programs spanning alpha-synuclein, GBA biology, gene therapy, and mechanistic repurposing.
Disease hub ALS pipelineTrack ALS programs across genetic targeting, stress-response biology, cell therapy, and platform-trial bets.
Disease hub FTD pipelineTrack FTD programs anchored in progranulin, GRN replacement, C9 biology, and other genetics-led strategies.
Disease hub Huntington's pipelineTrack Huntington's programs across gene therapy, antisense, allele-selective, and small-molecule huntingtin-lowering approaches.